BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang NN, Huang YF, Sun J, Chen Y, Tang ZM, Jiang JF. Meta-analysis of XRCC1 polymorphism and risk of female reproductive system cancer. Oncotarget 2017;8:28455-62. [PMID: 28415705 DOI: 10.18632/oncotarget.16090] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Ali R, Alabdullah M, Alblihy A, Miligy I, Mesquita KA, Chan SY, Moseley P, Rakha EA, Madhusudan S. PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers. Cancer Lett 2020;469:124-33. [PMID: 31669203 DOI: 10.1016/j.canlet.2019.10.035] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
2 Liu Z, Lin L, Yao X, Xing J. Association between polymorphisms in the XRCC1 gene and male infertility risk: A meta-analysis. Medicine (Baltimore) 2020;99:e20008. [PMID: 32358378 DOI: 10.1097/MD.0000000000020008] [Reference Citation Analysis]
3 Zhang XQ, Li L. A meta-analysis of XRCC1 single nucleotide polymorphism and susceptibility to gynecological malignancies. Medicine (Baltimore) 2021;100:e28030. [PMID: 34918657 DOI: 10.1097/MD.0000000000028030] [Reference Citation Analysis]